Clinical and experimental studies of intraperitoneal lipolysis and the development of clinically relevant pancreatic fistula after pancreatic surgery. Issue 5 (6th February 2019)

• Record Type: Journal Article
• Authors: Uchida, Y; Masui, T; Nakano, K; Yogo, A; Sato, A; Nagai, K; Anazawa, T; Takaori, K; Tabata, Y; Uemoto, S
• Is Part Of: British journal of surgery. Volume 106:Issue 5(2019)
• Page Start: 616
• Page End: 625
• Publication Date: 2019-02-06
• Subjects: Surgery -- Periodicals; 617.005
• DOI: 10.1002/bjs.11075
• Languages: English
• ISSNs: 0007-1323

Abstract

Abstract: Background: Visceral obesity is one of the risk factors for clinically relevant pancreatic fistula after pancreatic resection. The objective of this study was to evaluate the impact of intraperitoneal lipolysis on postoperative pancreatic fistula. Methods: The degree of intraperitoneal lipolysis was investigated by measuring the free fatty acid concentration in drain discharge in patients after pancreatic resection. An experimental pancreatic fistula model was prepared by pancreatic transection, and the impact of intraperitoneal lipolysis was evaluated by intraperitoneal administration of triolein (triglyceride) with, or without orlistat (lipase inhibitor). Results: Thirty-three patients were included in the analysis. The free fatty acid concentration in drain discharge on postoperative day 1 was significantly associated with the development of a clinically relevant pancreatic fistula ( P = 0·004). A higher free fatty acid concentration in drain discharge was associated with more visceral adipose tissue ( P = 0·009). In the experimental model that included 98 rats, intraperitoneal lipolysis caused an increased amount of pancreatic juice leakage and multiple organ dysfunction. Intraperitoneal administration of a lipase inhibitor reduced lipolysis and prevented deterioration of the fistula. Conclusion: Intraperitoneal lipolysis significantly exacerbates pancreatic fistula after pancreatic resection. Inhibition of lipolysis by intraperitoneal administration of a lipase inhibitor could be a promising therapy to reduce clinically relevant postoperative pancreatic fistula. Surgical relevance Clinically, there are two types of pancreatic fistula after pancreatic resections: harmless biochemical leak and harmful clinically relevant pancreatic fistula. Visceral obesity is one of the known risk factors for clinically relevant pancreatic fistula; however, the underlying mechanisms remained to be elucidated. Patients with clinically relevant pancreatic fistula had a higher free fatty acid concentration in the drain discharge, suggesting a relationship between intraperitoneal lipolysis and pancreatic fistula. The experimental model of pancreatic fistula demonstrated that intraperitoneal lipolysis caused deterioration in pancreatic fistula, suggesting that intraperitoneal lipolysis is one of the mechanisms that drives biochemical leakage to clinically relevant pancreatic fistula. Intraperitoneal administration of a lipase inhibitor prevented lipolysis as well as pancreatic fistula deterioration in the experimental model, suggesting a future clinical application for lipase inhibitors in prevention of clinically relevant pancreatic fistula. Graphical Abstract: Patients with clinically relevant pancreatic fistula had a significantly higher free fatty acid concentration in drain discharge, suggesting a relationship between intraperitoneal lipolysis and pancreatic fistula. The investigation in rat pancreatic fistula models demonstrated that intraperitoneal lipolysis caused deterioration of pancreatic fistula, indicating that intraperitoneal lipolysis is one of the mechanisms that drives biochemical leakage to clinically relevant pancreatic fistula. Potential target for prevention